CSIMarket
 


Surface Oncology Inc   (SURF)
Other Ticker:  
 
 

SURF's Net Income Growth by Quarter and Year

Surface Oncology Inc 's Net Income results by quarter and year




SURF Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -21.33 -24.05 67.35
III Quarter September - -23.24 -19.89 -15.77
II Quarter June -28.19 -25.21 -18.98 -14.81
I Quarter March -19.74 6.20 -15.56 22.57
FY   -47.93 -63.58 -78.48 59.34



SURF Net Income second quarter 2023 Y/Y Growth Comment
Surface Oncology Inc in the second quarter 2023 recorded net loss of $ -28.19 millions.

According to the results reported in the second quarter 2023, Surface Oncology Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Surface Oncology Inc ' s Net Income no change of % ranks overall at the positon no. in the second quarter 2023.




SURF Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Surface Oncology Inc 's second quarter 2023 Net Income $ -28.19 millions SURF's Income Statement
Surface Oncology Inc 's second quarter 2022 Net Income $ -25.21 millions Quarterly SURF's Income Statement
New: More SURF's historic Net Income Growth >>


SURF Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Surface Oncology Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SURF's II. Quarter Q/Q Net Income Comment
Recent results of -28.19 millions by Surface Oncology Inc look even more unfavourable if you take a look at -19.74 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry Surface Oncology Inc achieved highest sequential Net Income growth. While Surface Oncology Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SURF's II. Quarter Q/Q Net Income Comment
Current results of -28.19 millions by Surface Oncology Inc come out even more unfavourable compare to the net loss -19.74 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Surface Oncology Inc achieved highest sequential Net Income growth. While Surface Oncology Inc 's Net Income growth quarter on quarter, overall rank is .


Surface Oncology Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Net Income 12 Months Ending $ -92.51 $ -89.53 $ -63.59 $ -66.30 $ -62.96
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Surface Oncology Inc ' has realized cumulative trailing twelve months net loss of $ -93 millions in the Jun 30 2023 period.
The situation is worsening as the cumulative net loss is inflating from $ -89.53 millions in the twelve months ending a quarter before and $ -56.725 millions from the TTM period ending Jun 30 2022.

Surface Oncology Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Surface Oncology Inc ' has realized cumulative trailing twelve months net loss of $ -93 millions in the Jun 30 2023 period.
The situation is worsening as the cumulative net loss is inflating from $ -89.53 millions in TTM ending quarter Mar 31 2023 and $ -56.725 millions for the twelve months ending in the quarter a year ago Jack Jones wrote.

Surface Oncology Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
SURF's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for SURF's Competitors
Net Income Growth for Surface Oncology Inc 's Suppliers
Net Income Growth for SURF's Customers

You may also want to know
SURF's Annual Growth Rates SURF's Profitability Ratios SURF's Asset Turnover Ratio SURF's Dividend Growth
SURF's Roe SURF's Valuation Ratios SURF's Financial Strength Ratios SURF's Dividend Payout Ratio
SURF's Roa SURF's Inventory Turnover Ratio SURF's Growth Rates SURF's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2023
Ir med Inc 18.10%$ 18.104 millions
Resmed Inc 17.74%$ 17.740 millions
Dentsply Sirona Inc 16.44%$ 16.438 millions
Bruker Corporation16.30%$ 16.298 millions
Iqvia Holdings Inc 16.02%$ 16.016 millions
Regeneron Pharmaceuticals Inc 13.65%$ 13.649 millions
Vertex Pharmaceuticals Inc12.98%$ 12.980 millions
Shockwave Medical Inc 12.91%$ 12.914 millions
Becton Dickinson And Company12.74%$ 12.742 millions
Stryker Corp12.50%$ 12.500 millions
Steris Plc11.77%$ 11.769 millions
Ensign Group Inc10.88%$ 10.877 millions
Assertio Holdings inc 8.12%$ 8.118 millions
Universal Health Services Inc 6.63%$ 6.626 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com